FDA Regulatory Expertise
Navigate U.S. Market Entry with Confidence
Comprehensive FDA regulatory support for foreign pharmaceutical manufacturers entering the U.S. market. From
ANDA submissions to post-approval compliance.
ANDA Pathway Guidance
Complete support for Abbreviated New Drug Application submissions to the FDA.
- ANDA strategy development and planning
- Complete application preparation and review
- FDA correspondence and deficiency response
- Pre-submission feasibility assessment
Regulatory Dossier Preparation
Expert compilation of regulatory
documentation meeting FDA standards.
- CTD/eCTD format preparation
- Chemistry, Manufacturing, and Controls(CMC) documentation
- Bioequivalence study documentation
- Quality assurance and regulatory compliance review
U.S. Market Entry Strategy
Strategic planning for successful entry into
FDA-regulated markets.
- Competitive landscape analysis
- Regulatory pathway selection
- Timeline and resource planning
- Risk assessment and mitigation strategies
Post-Approval Compliance
Ongoing regulatory support to maintain FDA compliance after approval.
- Annual report preparation and submission
- Change control and supplement management
- FDA inspection readiness support
- Adverse event reporting and pharmacovigilance
Initial Assessment
Evaluate product viability and regulatory pathway
Strategy Development
Create comprehensive regulatory roadmap
Dossier Preparation
Compile and review all regulatory documentation
FDA Submission
Submit application and manage FDA correspondence
Ongoing Support
Post-approval compliance and maintenance
Why Choose UPPharmaceutical
Partner with regulatory experts who understand both pharmaceutical science and FDA requirements.
Proven Track Record
Years of experience successfully guiding pharmaceutical manufacturers through FDA approval processes.
Expert Team
Pharmacists, regulatory affairs specialists, and former FDA reviewers on our team.
High Success Rate
Demonstrated success in ANDA approvals and regulatory submissions across therapeutic categories.